Basket Trials for Intractable Cancer

This study was supported by the Shanghai Sailing Program [grant number 17YF1425200, 2017]; Chinese National Natural Science Funding [grant number 81702249, 2017]; Science and Technology Commission of Shanghai Municipality [grant number 17511103403, 2017]; The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge the experts from Refractory Malignancy Society of Chinese Medical Education Association for the consultation. References 1. Tao JJ, Schram AM, Hyman DM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med. (2018) 69:319–31. doi: 10.1146/annurev-med-062016-050343 PubMed Abstract | CrossRef Full Text | Google Scholar 2. Mcneil C. NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. (2015) 107:djv193. doi: 10.1093/jnci/djv193 PubMed Abstract | CrossRef Full Text | Google Scholar 3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. (2011) 364:2507–16. doi: 10.1056/NEJMoa1103782 PubMed Abstract | CrossRef Full Text | Google Scholar 4. Hainsworth JD...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionAccording to the study results, ginseng can be potentially used for cutaneous carcinoma as a chemopreventive agent by enhancing cell-mediated immunity and maintaining redox homeostasis with multiple components, targets and links.
Source: Journal of Ginseng Research - Category: Complementary Medicine Source Type: research
This study aimed to assess survival after TARE and to identify potential prognostic factors in this patient population. METHODS: Patients with unresectable and chemorefractory CRCLM treated with TARE at our institution between February 2006 and September 2015 were included in the study. Survival rate, hepatic tumor response, and potential prognostic factors were analyzed. RESULTS: In the 43 study patients, the mean follow-up was 15.0 ± 14.2 months, with a median survival of 13.0 months and 1-, 2-, 3-, 4-, and 5-year survival rates of 52.1%, 24.9%, 21.4%, 21.4%, and 7.1%, respectively. The mean activity of yt...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Authors: Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G Abstract INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) spans steatosis through nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC). NAFLD carries an increased risk of cardio-metabolic and liver-related events accounting for a substantial economic burden. Given that the natural history of NAFLD is critically dependent on the stage of fibrosis, non-invasively identifying the subgroup of patients at a higher risk of progressive disease is key. Areas covered: This review highlights the recent development...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Conclusion: PD-L1 expression in microenvironment predicted better PFS. The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 May 2019Source: Journal of Geriatric OncologyAuthor(s): Francesco Cuccia, Gianluca Mortellaro, Rosario Mazzola, Alessandra Donofrio, Vito Valenti, Antonella Tripoli, Domenica Matranga, Antonio Lo Casto, Giuseppe Failla, Giuseppe Di Miceli, Giuseppe FerreraAbstractObjectivesTo investigate whether assessment with two geriatric screening tools shows a correlation with clinical outcomes of patients aged 65 years or more, with early-stage Non-Small Cell Lung Cancer (es-NSCLC) treated with hypofractionated stereotactic radiotherapy.MethodsFrom March 2014 to June 2018 we retrospectively eva...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsTo engage frail older adults with CRC in preoperative exercise programs information on exercise should improve. Exercise programs should be easily accessible and take personal preferences, needs and abilities into account.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 May 2019Source: Journal of Geriatric OncologyAuthor(s): Elizabeth J. Siembida, Erin E. Kent, Keith M. Bellizzi, Ashley Wilder SmithAbstractObjectivesPhysical activity (PA) promotes physical functioning and health-related quality of life in older survivors of cancer. Using a population-based sample of Medicare Advantage beneficiaries, we aimed to characterize the survivors who reported discussing PA with their healthcare provider.Materials and MethodsData from the Surveillance, Epidemiology, and End Results (SEER) cancer registries was linked with the 2008–2014 Medicare Health Out...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Levofloxacin retained its therapeutic efficacy in patients assessed in a real-life setting, and high eradication rates were attained when it was administered as a single agent. A combination of an FQ with azithromycin induced a significant improvement of eradication rates. This strategy may be an interesting option in both first-referral and relapsing cases, although caution should be exercised when patients are at risk of developing arrhythmias, tendinitis, or other adverse effects.Chemotherapy
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
Date: Tuesday, 05 28, 2019; Speaker: Dr. Thuy Ngo, Research Assistant Professor, Oregon Health and Science University; Building 29B; 1H10
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Wednesday, 06 05, 2019; Speaker: Dana Pe'er, Sloan Kettering Institute; Nancy Allbritton, University of North Carolina at Chapel Hill; Steven Schiff, Pennsylvania State University; Denise Montell, University of California, Santa Barbara; Wendell Lim, University of California, San Francisco; Sanjay Jain, Johns Hopkins University; Christine Hendon, Columbia University; Ramsey Badawi, University of California, Davis; Deepika Mohan, University of Pittsburgh; Alexander Gimelbrant, Dana-Farber Cancer Institute; Amy Palmer, University of Colorado; Gabriel Lander, The Scripps Research Institute; Michael Angelo, Stanford Univ...
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Alimta | Bile | Bile Duct Cancer | Biology | Bladder Cancer | Brain | Brain Tumor | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer of the Uterus | Cancer Therapy | Carcinoma | Carcinoma of Unknown Primary | Cervical Cancer | Chemotherapy | Child Development | Children | China Health | Cholangiocarcinoma | Chronic Leukemia | Chronic Myeloid Leukaemia | Clinical Trials | Colon Cancer | Colorectal Cancer | Dermatology | Docetaxel | Education | Epidemiology | Funding | Gastric (Stomach) Cancer | Gastroenterology | Gastroschisis Repair | Genetics | Germany Health | Gleevec | Glioma | Grants | Hepatocellular Carcinoma | HER2 | Herceptin | Histiocytosis | Hospitals | Immunotherapy | Japan Health | Langerhans Cell Histiocytosis (LCH) | Leiomyosarcoma | Leukemia | Liver | Liver Cancer | Lung Cancer | Medical Training Application Service | Melanoma | Molecular Biology | Myeloma | Myeloproliferative Disorders | Neurology | Neuroscience | Non-Small Cell Lung Cancer | Nonmelanoma Skin Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Pediatrics | Prostate Cancer | Psychology | Radiation Therapy | Rare Diseases | Sarcomas | Science | Skin Cancer | Soft Tissue Sarcoma | Statistics | Study | Tarceva | Taxotere | Thyroid | Thyroid Cancer | Toxicology | Translocation | Universities & Medical Training | Urology & Nephrology | USA Health